"Ipca has received US Food and Drug Administration approval to manufacture and market metoclopramide tablets in 5 mg and 10 mg variants in the US, Lupin said in a filing to the Bombay Stock Exchange.
Ipca had earlier announced a strategic tie-up with US-based Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of domestic pharma major Ranbaxy Laboratories Ltd.
Metoclopramide tablets are also used in the treatment of nausea related to postoperative state and cancer chemotherapy.
Ipca would manufacture and Ranbaxy would market the drug in the US. "Ranbaxy will commercialise this product in the US market utilising its established marketing expertise and distribution network," the filing added.
This is the sixth such product approval received under the alliance from US FDA, it said.
Shares of Lupin were trading at Rs 577.05, up 1.02 per cent, in the afternoon trade on the BSE.
